CTX-10726 Clinical Trials (2026): 1 Studies for Endometrial Cancer & Gastroesophageal Cancer (GC)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 CTX-10726 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Endometrial Cancer & Gastroesophageal Cancer (GC)) and 70 total planned enrollment. 1 CTX-10726 clinical trial is actively recruiting at 4 U.S. sites across 4 states. Most recent activity: NCT07419841 (Nov 2028).
Where to Participate: All CTX-10726 Trial Sites in the U.S. (4 sites across 4 states)
Every actively recruiting CTX-10726trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT07419841 | Map |
| NY | START New York | Lake Success11042 | NCT07419841 | Map |
| SC | Prisma Health Cancer Institute | Greenville29605 | NCT07419841 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT07419841 | Map |
CTX-10726 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting CTX-10726 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | P1 | Gastroesophageal Cancer (GC) | 70 | May 2026 |
All CTX-10726 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | P1 | recruiting | 70 | Compass Therapeutics | May 2026 |
CTX-10726 clinical trials: frequently asked questions
- How many CTX-10726 clinical trials are there?
- 1 CTX-10726 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are CTX-10726 clinical trials recruiting in 2026?
- Yes — 1 CTX-10726 trial is actively recruiting in 2026, with 4 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is CTX-10726 being studied for?
- CTX-10726 is being studied for Endometrial Cancer, Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC). The trials are grouped by indication on this page.
- What phase is CTX-10726 in?
- CTX-10726 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors CTX-10726 clinical trials?
- The lead sponsor across the most CTX-10726 trials is Compass Therapeutics. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming CTX-10726as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: